A Phase 2b, Open-Label, Long-Term Extension Study to Evaluate the Safety and Pharmacodynamics of KRN23 in Adult Subjects with X-Linked Hypophosphatemia (XLH)
Administered By
Awarded By
Contributors
- Weber, Thomas Joseph Principal Investigator
Start/End
- March 15, 2015 - November 30, 2019